Susana Banerjee, B. Monk, E. Van Nieuwenhuysen, K. Moore, A. Oaknin, M. Fabbro, Nicoletta Columbo, D. O’Malley, R. Coleman, J. Pachter, A. Koustenis, Gloria Patrick, Lorna Leonard, R. Grisham
{"title":"ENGOT-ov60/GOG3052/RAMP 201: VS-6766(双RAF/MEK抑制剂)单独和联合defactinib (FAK抑制剂)治疗复发性低级别浆液性卵巢癌(LGSOC)的2期研究","authors":"Susana Banerjee, B. Monk, E. Van Nieuwenhuysen, K. Moore, A. Oaknin, M. Fabbro, Nicoletta Columbo, D. O’Malley, R. Coleman, J. Pachter, A. Koustenis, Gloria Patrick, Lorna Leonard, R. Grisham","doi":"10.1158/1535-7163.targ-21-p046","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":20348,"journal":{"name":"Poster Presentations - Proffered Abstracts","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Abstract P046: ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)\",\"authors\":\"Susana Banerjee, B. Monk, E. Van Nieuwenhuysen, K. Moore, A. Oaknin, M. Fabbro, Nicoletta Columbo, D. O’Malley, R. Coleman, J. Pachter, A. Koustenis, Gloria Patrick, Lorna Leonard, R. Grisham\",\"doi\":\"10.1158/1535-7163.targ-21-p046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":20348,\"journal\":{\"name\":\"Poster Presentations - Proffered Abstracts\",\"volume\":\"31 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Poster Presentations - Proffered Abstracts\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1535-7163.targ-21-p046\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Poster Presentations - Proffered Abstracts","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1535-7163.targ-21-p046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Abstract P046: ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)